Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
02
07
2022
accepted:
10
11
2023
medline:
29
11
2023
pubmed:
28
11
2023
entrez:
27
11
2023
Statut:
epublish
Résumé
Reliable real-world data on direct acting anti-retroviral (DAA) uptake and treatment outcomes are lacking for patients with hepatitis C virus (HCV) in sub-Saharan Africa. This study provides data on HCV DAA-based treatment outcomes, mortality, loss-to-follow up, and associated factors among patients in Eritrea. A multicenter retrospective observational cohort study was conducted in two tertiary hospitals in Asmara, Eritrea. A structured checklist was used to collect data from patient's cards. Descriptive and inferential statistics used included means (± Standard deviation (SD), medians (Interquartile range (IQR), chi-squire (χ
Identifiants
pubmed: 38012181
doi: 10.1038/s41598-023-47258-7
pii: 10.1038/s41598-023-47258-7
pmc: PMC10682448
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20792Informations de copyright
© 2023. The Author(s).
Références
Front Pharmacol. 2020 Sep 02;11:550205
pubmed: 32982753
MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):613-9
pubmed: 25055184
Viruses. 2020 Dec 29;13(1):
pubmed: 33383891
Drug Des Devel Ther. 2017 Feb 23;11:497-502
pubmed: 28260862
Aliment Pharmacol Ther. 2009 Sep 1;30(5):469-76
pubmed: 19508612
J Virus Erad. 2017 Jul 1;3(3):117-123
pubmed: 28758018
Harm Reduct J. 2021 Mar 31;18(1):38
pubmed: 33789691
N Engl J Med. 2016 Aug 25;375(8):767-77
pubmed: 27557303
World J Hepatol. 2017 Nov 28;9(33):1239-1252
pubmed: 29312527
BMJ Open. 2019 Jul 3;9(7):e029743
pubmed: 31272986
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126
pubmed: 30552056
Antivir Ther. 2017;22(4):307-312
pubmed: 27341294
World J Gastroenterol. 2021 Aug 7;27(29):4818-4830
pubmed: 34447228
BMC Med. 2017 Nov 20;15(1):204
pubmed: 29151365
J Infect Dis. 2020 Nov 27;222(Suppl 9):S745-S757
pubmed: 33245350
J Hepatol. 2016 Jul;65(1):33-39
pubmed: 26956698
J Infect Dev Ctries. 2018 Mar 31;12(3):178-182
pubmed: 31829993
Clin Infect Dis. 2015 Sep 1;61(5):730-40
pubmed: 25987643
Acta Biomed. 2019 May 23;90(2):187-196
pubmed: 31124995
Clin Infect Dis. 2011 Apr 1;52(7):889-900
pubmed: 21427396
J Prev Med Public Health. 2021 Jul;54(4):251-258
pubmed: 34370938
Arch Virol. 2022 Mar;167(3):717-736
pubmed: 35089390
Cureus. 2021 Aug 16;13(8):e17237
pubmed: 34540464
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):910-919
pubmed: 29132760
Case Reports Hepatol. 2022 Mar 11;2022:3556780
pubmed: 35309181
Antiviral Res. 2015 Mar;115:83-93
pubmed: 25545071
J Viral Hepat. 2020 Dec;27(12):1270-1283
pubmed: 32964615
World J Gastroenterol. 2021 Jul 28;27(28):4603-4638
pubmed: 34366625
BMC Infect Dis. 2018 Jun 7;18(1):264
pubmed: 29879912
Clin Microbiol Infect. 2016 Oct;22(10):826-832
pubmed: 27592089
World J Gastroenterol. 2014 Mar 21;20(11):2927-40
pubmed: 24659883
Nat Rev Dis Primers. 2017 Mar 02;3:17006
pubmed: 28252637
Infect Dis Ther. 2020 Dec;9(4):851-866
pubmed: 32897520
Curr Treat Options Infect Dis. 2020;12(3):296-309
pubmed: 32837340
World J Gastroenterol. 2014 Mar 21;20(11):2785-800
pubmed: 24659872
BMC Gastroenterol. 2021 Jun 12;21(1):259
pubmed: 34118889
J Viral Hepat. 2021 Jan;28(1):147-158
pubmed: 32935438